Sign in
Not yet recruitingPhase 1/2

Testing the capsule HS-10561 in healthy adults and people with chronic spontaneous urticaria

Tests HS-10561 against placebo in healthy adults and people with chronic spontaneous urticaria.

Key facts

Who runs it
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
150 people, planned
Started
31 Mar 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HS-10561
  • Placebo
Record updated
7 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults for a single-dose part, and adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger) for the multiple-dose and phase 2 parts.

Age
Healthy volunteers in the single-dose part: 18-45 years. Multiple-dose and phase 2 parts: 18-65 years.
Sex
All sexes. Men and women must agree to use highly effective birth control until 30 days after the last dose.
Disease stage
Single-dose part: healthy, weight at least 50 kg (110 lb) for men and 40 kg (88 lb) for women, body mass index 18-30 kg/m2. Other parts: chronic spontaneous urticaria diagnosed for ≥6 months.

Main reasons for not taking part

  • Hives with a clear main or only trigger (chronic inducible urticaria)
  • Other diseases that cause hives or swelling (angioedema), or other long-lasting itchy skin diseases
  • Pregnant or breastfeeding women, or planning a pregnancy during the study
  • Healthy volunteers: past serious disease of major body systems, or past tumors
  • Important abnormal test or exam results that the study doctor judges risky

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Written informed consent must be obtained before any assessment is performed.(SD)
  • Healthy adults aged 18-45 years (inclusive) at the time of signing the informed consent form;(SD)
  • Male participants weighing ≥ 50 kg and female participants weighing ≥ 40 kg; body mass index (weight/square of height (kg/m2)) within the range of 18-30 kg/m2 (inclusive);(SD)
  • Female participants and male participants (including their female partners) agree to use highly effective methods of contraception from the date of signing the informed consent form until 30 days after the last dose;(SD)
  • Without history of severe respiratory, gastrointestinal (such as inflammatory bowel disease, Crohn's disease, chronic diarrhea, etc.), neurological, circulatory, urinary, endocrine, musculoskeletal, immune system disorders, or a history of tumors prior to screening.(SD)
  • Written informed consent must be obtained before any assessment is performed.(MD and Phase 2)
  • Healthy adults aged 18-65 years (inclusive) at the time of signing the informed consent form;(MD and Phase 2)
  • Have been diagnosed with chronic spontaneous urticaria for ≥6 months at the time of screening;(MD and Phase 2)
  • Female participants and male participants (including their female partners) agree to use highly effective methods of contraception from the date of signing the informed consent form until 30 days after the last dose.(MD and Phase 2)

Who cannot take part

  • Any physiological or psychological condition or disease, as determined by the investigator, that could increase the risk, affect the participants' compliance, or impact the participants' ability to complete the study.(SD)
  • Other diseases with symptoms of urticaria or angioedema;(MD and Phase 2)
  • Other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results;(MD and Phase 2)
  • Have clinically significant abnormalities in vital signs, physical examination, laboratory tests, chest X-ray/CT, or abdominal ultrasound during the screening period, which, as assessed by the investigator, may increase the participants' risk or affect the scientific validity of the study;(SD)
  • Females with a positive blood pregnancy test, breastfeeding females, or participants planning to become pregnant during the study period;(SD)
  • Chronic urticaria with a clear primary or sole trigger (chronic inducible urticaria);(MD and Phase 2)
  • Clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria);(MD and Phase 2)
  • Pregnant or nursing (lactating) women.(MD and Phase 2)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo-controlled phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HS-10561 capsule in healthy Chinese adults and patients with chronic spontaneous urticaria.

The 4 groups in the trial

  • HS-10561 Dose 1Treatment being tested

    Treatment: HS-10561

  • HS-10561 Dose 2Treatment being tested

    Treatment: HS-10561

  • HS-10561 Dose 3Treatment being tested

    Treatment: HS-10561

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.
Plain-language title
Testing the capsule HS-10561 in healthy adults and people with chronic spontaneous urticariaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06864507, who can take part
Record updated
7 March 2025